Board Meeting Intimation for Results
Concord Drugs Ltd has informed BSE that the meeting of the Board of Directors of the Company will be held on November 14, 2016, to consider The following:- Un - Audited financial results for the quarter ended September 30, 2016.- Limited Review Report for the quarter ended September 30, 2016. Limited Review Report for June 30, 2016
Concord Drugs Ltd has informed BSE about : 1. Standalone Limited Review for the period ended June 30, 2016 Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended September 30, 2016
Concord Drugs Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended September 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Shareholding for the Period Ended September 30, 2016
Concord Drugs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2016. For more details, kindly Click here Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Concord Drugs Ltd has informed BSE regarding the details of Voting results at the 21st Annual General Meeting (AGM) of the Company held on September 29, 2016, under Regulation 44(3) of SEBI (LODR) Regulations, 2015 along with Scrutinizer's Report and Proceedings of the Meeting in this regard. Fixes Book Closure for AGM
Concord Drugs Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from September 24, 2016 to September 29, 2016 (both days inclusive) for the purpose of 21st Annual General Meeting (AGM) of the Company to be held on September 29, 2016. Standalone Financial Results for June 30, 2016
Concord Drugs Ltd has informed BSE about : 1. Standalone Financial Results for the period ended June 30, 2016 Closure of Trading Window
Concord Drugs Ltd has informed BSE that the trading window in respect of the Companys Securities shall remain closed for all the Directors/Officers/Designed Employees of the Company from the trading hours on August 02, 2016 till close of the trading hours on August 16, 2016 as per the code of Internal Procedure and Conduct for Prevention of Insider Trading adopted by the Company for declaration of unaudited financial results for the quarter ended June 30, 2016. Board Meeting Intimation for Results
Concord Drugs Ltd has informed BSE that the meeting of the Board of Directors of the Company will be held on August 13, 2016, inter alia, to consider the following:1. Un - Audited financial results for the quarter ended June 30, 2016.2. Limited Review Report for the quarter ended June 30, 2016. Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended June 30, 2016
Concord Drugs Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended June 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.